Mount Yale Investment Advisors LL recently announced the acquisition of new stake in Bio-Path Holdings Inc. (NASDAQ:BPTH). This fresh investment now brings its stake to 0.32% valued currently at $38279.0. In addition, Renaissance Technologies LLC raised its holdings by 600.0 to 18600.0 shares. And Dimensional Fund Advisors LP has lifted its position by 26.57% or 3443.0 shares – to 16403.0 shares.
With over 88650.0 Bio-Path Holdings Inc. (BPTH) shares trading Tuesday and a closing price of $2.07 on the day, the dollar volume was approximately $0.18 million. The shares have shown a negative half year performance of -43.90% and its price on 01/24/23 gained nearly 7.26%. Currently, there are 7.96M common shares owned by the public and among those 7.93M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for BPTH have a consensus price objective of $11.00. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $9.00. The average price target is 81.18% above its recent price level and an upside to the estimated low will see the stock gain 77.0% over that period. But an upside of 84.08% will see the stock hit the forecast high price target while median target price for the stock is $11.00.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Bio-Path Holdings Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.12 million shares of the company’s stock, all valued at over $0.18 million. Vanguard Extended Market Index Fu bought 151.0 shares to see its total holdings expand to 95129.0 shares valued at over $0.14 million and representing 1.20% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.46% of the shares outstanding.
Shares of Bio-Path Holdings Inc. (NASDAQ: BPTH) opened at $1.96, up $0.03 from a prior closing price of $1.93. However, the script later moved the day high at 2.0900, up 7.26%. The company’s stock has a 5-day price change of 7.81% and -35.51% over the past three months. BPTH shares are trading 37.09% year to date (YTD), with the 12-month market performance down to -43.29% lower. It has a 12-month low price of $1.27 and touched a high of $4.48 over the same period. BPTH has an average intraday trading volume of 65.93K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 25.43%, 33.19%, and -31.35% respectively.
Institutional ownership of Bio-Path Holdings Inc. (NASDAQ: BPTH) shares accounts for 5.80% of the company’s 7.96M shares outstanding. Mutual fund holders own 2.11%, while other institutional holders and individual stakeholders account for 3.67% and 2.05% respectively.
It has a market capitalization of $16.37M and a beta (3y monthly) value of 1.28. The earnings-per-share (ttm) stands at -$1.96. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.93% over the week and 6.93% over the month.
Analysts forecast that Bio-Path Holdings Inc. (BPTH) will achieve an EPS of -$0.45 for the current quarter, -$0.42 for the next quarter and -$1.6 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.48 while analysts give the company a high EPS estimate of -$0.43. Comparatively, EPS for the current quarter was -$0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 45.10%, and 8.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Bio-Path Holdings Inc. (BPTH) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BPTH, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on March 11, 2021, with the firm’s price target at $13. H.C. Wainwright coverage for the Bio-Path Holdings Inc. (BPTH) stock in a research note released on November 13, 2017 offered a Buy rating with a price target of $1.50. Maxim Group was of a view on August 10, 2016 that the stock is Buy, while Rodman & Renshaw gave the stock Buy rating on April 18, 2016, issuing a price target of $5. Maxim Group on their part issued Buy rating on June 02, 2014.